Geron Corp (GERN)

[healthywelth]

ALL do your own DD, but here is a straight out simple fact. Do not lose sight of this one. Bloomberg posted the JNJ response of the job posting being a non-event one way or another for the imetelstat position at 12.51PM EST. That was right at about $4.95/shr. Instead of bleeding off in to a death spiral down to unchanged for the rest of the session, you might notice for 3 hours and 10 minutes after that the stock only traded higher, finally finishing at the close we know of $5.19/shr. For over 3 hours in to the close it only traded higher. Don't tell me today wasn't a good sign and that JNJ telegraphed the positive continuation decision. Any other change of story like that would have sent this back to $4/shr. even in 30 minutes or less. We go higher. AFTER HOURS $5.31

p.s. J&J still not removed from Job post - (IMETELSTAT) The Strategic Pricing Manager for Imbruvica & Imetelstat will work closely with the Compound Market Access Leaders, the EMEA Pricing Hub, Global Pricing and EMEA Operating Companies in managing strategic pricing within the Hematology therapy area.

•The indications of interest for Imbruvica and Imetelstat are as follows:

•Imbruvica tablet formulation


•Imbruvica 1L+ Waldenstrom’s


•Imbruvica 1L CLL elderly, unfit (I + G)


•1L DLBCL (non-GCB)


•Imbruvica combination with rituximab


•Imbruvica DLBCL front-line


•Imbruvica CLL front-line


•Imbruvica chronic GVHD


•Imbruvica CLL young and fit


•Imbruvica FL relapsed/refractory


•Imbruvica MCL front-line maintenance


•Imetelstat Lower Risk MDS


•Imetelstat AML induction ineligible

https://jobs.jnj.com/jobs/00001DCC?lang=en-us